Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
17.72
-0.38 (-2.10%)
Jul 30, 2025, 2:57 PM - Market open

Company Description

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally.

The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.

The company was founded in 2017 and is based in Zug, Switzerland.

Oculis Holding AG
Oculis Holding AG logo
CountrySwitzerland
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees49
CEORiad Sherif

Contact Details

Address:
Bahnhofstrasse 20
Zug, 6300
Switzerland
Phone41-41-711-3960
Websiteoculis.com

Stock Details

Ticker SymbolOCS
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyCHF
CIK Code0001953530
ISIN NumberCH1242303498
SIC Code2834

Key Executives

NamePosition
Dr. Riad Sherif M.B.A., M.D.Chief Executive Officer and Director
Sylvia CheungChief Financial Officer
Gudrun Bachmann Ph.D.Chief Technology Officer
Dr. Ramin Tadayoni M.D., Ph.D.Chief Scientific Officer
Daniel S. Char J.D.Chief Legal Officer
Virginia R. DeanChief Human Resources Officer
Páll Ragnar JóhannessonChief Business Officer
Rebecca WeilChief Commercial Officer
Dr. Snehal Shah Pharm.D.President of Research and Development
Dr. Sharon Klier M.D., M.P.H.Chief Development Officer

Latest SEC Filings

DateTypeTitle
Jun 5, 2025S-8Securities to be offered to employees in employee benefit plans
Jun 5, 20256-KReport of foreign issuer
May 9, 20256-KReport of foreign issuer
May 8, 20256-KReport of foreign issuer
Apr 15, 20256-KReport of foreign issuer
Mar 14, 2025144Filing
Mar 11, 202520-FAnnual and transition report of foreign private issuers
Mar 11, 20256-KReport of foreign issuer
Feb 14, 20256-KReport of foreign issuer
Feb 14, 2025424B5Filing